The 59th Annual ASH meeting & exposition was held was held December 9-12, 2017 in Atlanta, GA. The following are the 16 posters presented by the Bing Center for Waldenstrom's Macroglobulinemia.
Click on the poster to download a full size PDF version. For more information about ASH-2017, please visit http://www.hematology.org/Annual-Meeting/
Acquired Von Willebrand Disease in Patients with Waldenstrom Macroglobulinemia
Jorge J. Castillo, Joshua N. Gustine, Kirsten Meid, Toni E. Dubeau, Patricia Severns, Steven P. Treon
Aberrant HCK Survival Signaling By Mutated MYD88 Requires PAX5 in Waldenstrom's Macroglobulinemia and ABC DLBCL Cells
Xia Liu, Jiaji Chen, Manit Munshi, Lian Xu, Nicholas Tsakmaklis, Maria Demos, Amanda Kofides, Gloria Chan, Zachary Hunter, Christopher Patterson, Robert Manning, Philip Brodsky, Joshua Gustine, Patricia Severns, Toni Dubeau, Jorge Castillo, Steven Treon, and Guang Yang
Mutated MYD88 Homozygosity Is Increased in Previously Trated Patients with Waldenstrom's Macroglobulinemia, and Associates with CXCR4 Mutation Status and Ibrutinib Exposure
Nickolas Tsakmaklis, Lian Xu, Joshua Gustine, Robert J. Manning, Guang Yang, Jie Chen, Xia Liu, Jiaji Chen, Maria Demos, Gloria G. Chan, Christopher J. Patterson, Jorge J. Castillo, Steven P. Treon and Zachary R. Hunter
Prospective Phase II Study of Ixazomib, Dexamethasone and Rituximab in Previously Untreated Patients with Waldenstrom's Macroglobulinemia
Jorge J. Castillo, Kirsten Meid, Joshua N. Gustine, Toni E. Dubeau, Patricia Severns, Steven P. Treon
Bendamustine and Bortezomib-Containing Regimens Produce Higher Response Rates and More Durable Responses Versus Cyclophosphamide-Based Therapy in Frontline WM
Jorge J. Castillo, Joshua N. Gustine, Kirsten Meid, Toni E. Dubeau, Patricia Severns, Steven P. Treon
Mutated MYD88 Activates the BCR Component SYK and Provides a Rationale Therapeutic Target in WM
Manit Munshi, Xia Liu, Jiaji Chen, Lian Xu, Nickolas Tsakmaklis, Maria Demos, Amanda Kofides, Gloria Chan, Zachary R. Hunter, Christopher J. Patterson, Robert Manning, Philip Brodsky, Joshua Gustine, Patricia Severns, Toni Dubeau, Jorge J. Castillo, Steven P. Treon, and Guang Yang
Long-Term Follow-Up of Previously Treated Patients Who Received Ibrutinib for Symptomatic WM: Update of Pivotal Clinical Trial
Steven P. Treon, Kirsten Meid, Joshua Gustine, Kurt S. Bantilan, Toni Dubeau, Patricia Severns, Guang Yang, Lian Xu, Christopher Patterson, Irene M. Ghobrial, Jacob Laubach, Zachary R. Hunter, Jorge J. Castillo, Maria L. Palomba, and Ranjana H. Advani.
Ibrutinib Is Highly Active As First Line Therapy in Symptomatic WM
Steven P. Treon, Joshua N. Gustine, Kirsten Meid, Toni Dubeau, Patricia Severns, Christopher Patterson, Lian Xu, Guang Yang, Maria Demos, Amanda Kofides, Jiaji Chen, Manit Munshi, Nickolas Tsakmaklis, Gloria Chan, Andrew Yee, Noopur Raje, Elizabeth O'Donnell, Zachary R. Hunter, and Jorge Castillo
Long-Term Analysis of a Prospective Phase II Clinical Trial of Carfilzomib, Rituximab and Dexamethasone (CaRD) in WM
Kirsten Meid, MPH, , Toni Dubeau, NP, Patricia Severns, NP, Joshua Gustine, MPH, Irene M. Ghobrial, MD, Jorge J. Castillo, MD, and, Steven P. Treon, MD, PhD, Bing Center for Waldenstrom’s Macroglobulinemia at the Dana-Farber
Abnormal Splicing Patterns and Novel Intron Retentions Affect Genes Regulating Splicing, NF-Kb, ERK1/2, and TP53 in WM
Zachary R. Hunter, Nickolas Tsakmaklis, Lian Xu, Maria Demos, Amanda Kofides, Gloria G. Chan, Jiaji Chen, Manit Munshi, Xia Liu, Joshua Gustine, Christopher J. Patterson, Toni Dubeau, Patricia Severns, Jorge Castillo, Guang Yang, Nikhil Munshi, Kenneth Anderson and Steven P. Treon
MYD88 Mutation Status Impacts Overall Survival and Risk of Histological Transformation in WM
Steven P. Treon, Zachary R. Hunter, Joshua Gustine, Kirsten Meid, Lian Xu, Xia Lu, Guang Yang, Manit Munshi, Robert Manning, Nickolas Tsakmaklis, Maria Demos, Amanda Kofides, Maria Luisa Guerrera, Jiaji Chen, Christopher J. Patterson, Toni Dubeau, Patricia Severns, and Jorge J. Castillo.
The Genomic Landscape of MYD88 Wild-Type WM Is characterized By Somatic Mutations in TBL1XR1, the CBM Complex, and NFKB2
Zachary Hunter, Nickolas Tsakmaklis, Maria Demos, Amanda Kofides, Lian Xu, Gloria Chan, Jiaji Chen, Manit Munsh, Xia Liu, Joshua Gustine, Christopher Patterson, Toni Dubeau, Patricia Severns, Jorge J. Castillo, Guang Yang and Steven P Treon
Survival Rates and Clinical Characteristics of Young Patients with WM
Amaara Babwah, MS, Joshua Gustine, MPH, Kirsten Meid, MPH, Toni Dubeau, NP, Patricia Severns, NP, Steven P. Treon, MD, PhD and Jorge J. Castillo, MD
Impact of Ibrutinib Dose Intensity on Patient Outcomes in Previously Treated WM
Joshua N. Gustine, Kirsten Meid, Toni Dubeau, Patricia Severns, M. Lia Palomba, Ranjana H. Advani, Steven P. Treon, and Jorge J. Castillo
Patient-reported Symptoms during Ibrutinib Holds: A Withdrawal Syndrome
Jorge J. Castillo, Joshua N. Gustine, Kirsten Meid, Toni Dubeau, Patricia Severns, and Steven P. Treon
Differential Diagnosis of Suspected MYD88 Wild_Type WM Includes Other Malignant and Non-Malignant IgM Secreting Entities, Including Frequent Cases of IgM Myeloma
Steven P. Treon, Zachary R. Hunter, Joshua Gustine, Kirsten Meid, Lian Xu, Xia Lu, Guang Yang, Manit Munshi, Robert Manning, Nickolas Tsakmaklis, Maria Demos, Amanda Kofides, Maria Luisa Guerrera, Jiaji Chen, Christopher J. Patterson, Toni Dubeau, Patricia Severns, and Jorge Castillo.